The QualityStocks Daily Tuesday, May 20th, 2025

Today's Top 3 Investment Newsletters

TechMediaWire(SYTA) $8.1900 +101.23%

MarketClub Analysis(NRXS) $3.9900 +75.77%

MarketBeat(TNMG) $0.9100 +52.71%

The QualityStocks Daily Stock List

Digital Brands Group (DBGI)

QualityStocks, StockEarnings, Premium Stock Alerts, BUYINS.NET, Schaeffer's, The Online Investor and InvestorPlace reported earlier on Digital Brands Group (DBGI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Digital Brands Group Inc. (NASDAQ: DBGI) is engaged in the provision of apparel under differ-ent brands on wholesale and direct-to-consumer basis.

The firm has its headquarters in Austin, Texas and was incorporated in 2012. Prior to its name change, the firm was known as Denim L.A. Inc. It operates as part of the retail and whole-discretionary industry, under the consumer discretionary sector, in the retail-discretionary sub-industry and serves consumers in the U.S.

The company operates through the Bailey 44 and DSTLD segments. It brings like-minded direct-to-consumer names under a single portfolio to share data, infrastructure and operational resources in an attempt to reduce redundant fixed costs that are expensive to maintain and difficult to estab-lish. The elimination of administrative responsibilities for their brands allows innovation and crea-tivity to be stimulated and enables brands to be committed to the product and customer experience.

The enterprise provides luxury men’s suiting under the ACE Studios brand and denims under the DSTLD brand. It is also involved in designing, manufacturing and selling women’s apparel, which includes rompers, jackets, sets, bottoms, jumpsuits, tops and dresses, under the Bailey 44 brand. It sells its products directly to the end consumer via its websites, as well as via its own showrooms, select department stores and wholesale channels in specialty stores.

Digital Brands Group (DBGI), closed Tuesday's trading session at $13.89, up 49.3548%, on 123,664 volume. The average volume for the last 3 months is 22,610 and the stock's 52-week low/high is $1.03/$114.82.

Eyenovia Inc. (EYEN)

QualityStocks, MarketBeat, StreetInsider, StockMarketWatch, Premium Stock Alerts, InsiderTrades, Trading Concepts, TradersPro, Daily Trade Alert, MarketClub Analysis and BUYINS.NET reported earlier on Eyenovia Inc. (EYEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eyenovia Inc. (NASDAQ: EYEN) is a clinical stage biopharmaceutical firm that is focused on the development of its MAP (microdose array print) platform technology.

The firm has its headquarters in New York and was incorporated in 2014, on March 12th by Sean Ianchulev. Prior to its name change in May 2014, the firm was known as PGP Holdings V. Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in the United States.

The company is party to a license agreement with Arctic Vision Ltd, which entails the development and commercialization of MicroLine and MicroPine in South Korea and China. It is also party to a license agreement with Bausch Health Ireland Ltd, which involves the development and commer-cialization of MicroPine in Canada and the United States.

The enterprise’s pipelines are focused on developing therapeutic indications for patients with pres-byopia indications, progressive myopia or age-related near vision impairment. Its product portfolio is comprised of MicroPine, which has been developed to treat pediatric myopia progression. It also develops MicroLine, which has been developed to improve near vision in individuals with presby-opia. In addition to this, the enterprise develops MydCombi, which has indications for pharmaceu-tical mydriasis.

Eyenovia Inc. (EYEN), closed Tuesday's trading session at $1.67, up 47.7876%, on 49,961,376 volume. The average volume for the last 3 months is 9,787,516 and the stock's 52-week low/high is $0.85/$124.8.

Ares Strategic Mining (ARSMF)

We reported earlier on Ares Strategic Mining (ARSMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ares Strategic Mining Inc. (OTCQX: ARSMF) (CNSX: ARS) (FRA: N8I1) is a junior natural resource mining firm that is focused on the identification and mining of fluor-spar properties.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2009, on November 20th. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The company is focused on exploiting, producing and supplying metspar and acidspar to the markets. Its projects include Liard Property, Lost Sheep and The Iron and Va-nadium Ridge. The company holds 100% interest in five properties located in Ontario, Canada; and in the Liard Fluorspar property, which includes over 55 mineral claims spanning across 55,000 acres in British Columbia; a well as the Lost Sheep Fluoride Mine, which comprises of 67 claims covering an area of approximately 1,447 acres lo-cated in western Utah, U.S. The Lost sheep mine is situated at the Spor Mountain area, Juab County, roughly 214 km south-west of Salt Lake City. It also holds 20% interest in the Vanadium Ridge property, which comprises of 20 mining claims that cover an area of about 5,200 acres located in the Kamloops, British Columbia. In addition to this, the company holds interest in the Campbell-Croster fluorspar project in Kentucky.

The enterprise, which possesses the only permitted fluorspar mine in the United States, is focused on acquiring new professional personnel and new strategic partners and building a global customer base. This may in turn help generate shareholder value.

Ares Strategic Mining (ARSMF), closed Tuesday's trading session at $0.23, up 38.5542%, on 701,518 volume. The average volume for the last 3 months is 6,556,795 and the stock's 52-week low/high is $0.088/$0.23.

Adriatic Metals (ADMLF)

We reported earlier on Adriatic Metals (ADMLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adriatic Metals PLC (OTCQX: ADMLF) (ASX: ADT) (LON: ADT1) (FRA: 3FN) is a mining exploration and development firm that is focused on exploring for and de-veloping precious metal and base metal deposits.

The firm has its headquarters in Cheltenham, the United Kingdom and was incorpo-rated in 2017, on February 3rd by Paul B. Cronin. It operates as part of the other indus-trial metals and mining industry, under the basic materials sector. The firm serves con-sumers around the globe.

The enterprise primarily explores for zinc, gold, lead, silver, barite and copper deposits. Its flagship project is the world-class Vares Silver project, which is located approxi-mately 50 km north of the Bosnia and Herzegovina capital Sarajevo, in the district of Vares. Through its wholly-owned Eastern Mining d.o.o subsidiary, it owns approxi-mately 41 km2 of Vares Project concession. The enterprise also operates the Raska zinc project located in Serbia, which is an advanced exploration project that exhibits excep-tionally high grades of the base and precious metals. This project comprises of 2 brownfield polymetallic prospects dubbed Sastavci and Kizevak, as well as various other greenfield targets across its approximately 92km2 of landholding. In addition to this, it develops various polymetallic projects in the Balkans.

The company remains focused on achieving its primary objective to develop resource opportunities through the diversification of its assets and extending the mine life of its Vares project. This will not only enable them to bring Vares to production but also help deliver long-term growth, which will greatly benefit its shareholders.

Adriatic Metals (ADMLF), closed Tuesday's trading session at $2.895, up 18.1633%, on 171,018 volume. The average volume for the last 3 months is 659,125 and the stock's 52-week low/high is $1.71/$3.37.

Relmada Therapeutics (RLMD)

QualityStocks, MarketBeat, Streetwise Reports, Wallstreetbuzz, StockMarketWatch, Investors Alley, Schaeffer's, BUYINS.NET, InsiderTrades, Premium Stock Alerts, StreetAuthority Financial, Dividend Opportunities, Trades Of The Day, MarketClub Analysis, FreeRealTime, InvestorPlace, Daily Trade Alert, Investopedia, PCG Advisory, Penny Stock Bets, ProfitableTrading, WallstreetsHotteststocks, SmallCap Network, SmallCapNetwork, The Observer, Trade of the Week, TradersPro and Prism MarketView reported earlier on Relmada Therapeutics (RLMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Relmada Therapeutics Inc. (NASDAQ: RLMD) (FRA: 4E2) is a clinical-stage bio-technology firm that is focused on the development of a range of products to help treat central nervous system illnesses and other disorders.

The firm has its headquarters in Coral Gables, Florida and was incorporated in 2012, on May 31st by Paolo Manfredi. It operates as part of the biotechnology industry, un-der the healthcare sector. The firm serves consumers around the globe.

The public specialty pharmaceutical company develops various established drug prod-ucts. It believes that its REL-1017 candidate has the potential to transform the current neuropharmacological approach to major depressive disorder.

The enterprise’s product pipeline is comprised of a novel NMDA receptor (NMDAR) channel blocker dubbed REL-1017, which preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. This formulation is in development for both the adjunctive or monotherapy treatment of major depressive disorder. It also develops an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol dubbed LevoCap ER, to help manage pain; and a proprietary topical dosage form of the local anesthetic mepivacaine known as MepiGel, for the treatment of painful peripheral neuropathies, including painful HIV-associated neuropathy, postherpetic neuralgia and painful diabetic neuropathy.

Relmada Therapeutics (RLMD), closed Tuesday's trading session at $0.597, up 17.2888%, on 1,575,895 volume. The average volume for the last 3 months is 95,860 and the stock's 52-week low/high is $0.2404/$4.47.

Zion Oil & Gas, Inc. (ZNOG)

We reported earlier on Zion Oil & Gas, Inc. (ZNOG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Zion Oil & Gas, Inc. operates as an oil and gas exploration company in Israel. It explores for oil and gas onshore in Israel on its 99,000-acre Megiddo-Jezreel license area. Fundamentally, it is exploring for Isra-el’s Political and Economic Independence. Established in 2000, Zion Oil & Gas has its corporate head-quarters in Dallas, Texas. It also has its Israel office in Caesarea. The Company’s shares trade on the OTCQB.

Zion Oil & Gas’ vision is to find oil and/or natural gas in Israel. The Company’s Founder and Chairman, Mr. John Brown, provides the broad vision and goals for Zion Oil & Gas. The Company says that the initi-atives taken by its Management as it explores for oil and gas in Israel are founded on modern science and good business practices. Zion’s oil and gas exploration activities are supported by suitable geological, geophysical, as well as other science-based studies and surveys.

Mr. Brown has wide-ranging management, marketing, and sales experience, serving as Corporate Direc-tor of Purchasing at GTE Valeron, a subsidiary of GTE Corporation from 1966 to 1986. He was Corporate Director of Procurement at Magnetek, Inc. during 1988-89. Until 2012, Mr. Brown was also an Officer and Director of M&B Holding, Inc.

Zion Oil & Gas, Inc. (ZNOG), closed Tuesday's trading session at $0.189, up 16.3793%, on 5,242,392 volume. The average volume for the last 3 months is 12,351,720 and the stock's 52-week low/high is $0.03/$0.2699.

NervGen Pharma Corp. (NGENF)

QualityStocks, TradersPro, MarketBeat and AllPennyStocks reported earlier on NervGen Pharma Corp. (NGENF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NervGen Pharma Corp. is a regenerative medicine company listed on the OTC Markets Group’s OTCQX. The Company’s commitment is to creating leading-edge solutions for the treatment of nerve damage. This includes spinal cord and peripheral nerve injury. The Company’s lead compound is NVG-291. NervGen Pharma has its corporate headquarters in Vancouver, British Columbia.

NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ). This is a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regener-ation of damaged nerves and improvement of nerve function in animal models for diverse medical con-ditions. Research has been conducted on other applications of PTPs including MS, stroke, cardiac ar-rhythmia, and Alzheimer’s Disease.

In addition, the Company continues to research secondary applications including multiple sclerosis, acute myocardial infarction induced arrhythmia (AMI, normally known as a heart attack), stroke and other neurodegenerative diseases. NervGen’s plan is to begin a Phase 1 human clinical trial for its lead compound, NVG-291, in early 2020 under an Investigational New Drug application with the US Food and Drug Administration (FDA).

NervGen Pharma is advancing NVG-291 for the treatment of spinal cord injury as it believes this indica-tion is a significant opportunity due to the present lack of non-surgical solutions in the market, the con-siderable impact on quality of life, and the high cost burden to the healthcare system. The Company’s belief is that NVG-291 as a therapy could alleviate or improve upon the symptoms and conditions asso-ciated with spinal cord injury. It also believes that NVG-291 as a therapy could empower these patients to live more active and productive lives.

NervGen Pharma Corp. (NGENF), closed Tuesday's trading session at $4.21, up 15.8184%, on 815,990 volume. The average volume for the last 3 months is 212,143,639 and the stock's 52-week low/high is $1.2/$4.4.

JBDI Holdings (JBDI)

Premium Stock Alerts reported earlier on JBDI Holdings (JBDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

JBDI Holdings Limited (NASDAQ: JBDI) is a holding company focused on revitalization, re-conditioning, and recycling of plastic carboys, open metal and plastic drums, and intermediate bulk containers.

The firm has its headquarters in Singapore and was incorporated in 1983. Prior to its name change in 1984, the firm was known as Good Industries Pte. Limited. It operates as part of the specialty retail industry, under the consumer cyclical sector. The firm serves consumers around the globe, with a focus on those in Southeast Asia and the United States.

The company operates as a subsidiary of E U Holdings Pte. Limited. JBDI’s aim is to offer envi-ronmentally friendly, efficient, innovative and reliable products and services to help its clients move towards a zero environmental impact footprint as well as save costs and achieve a better allocation of resources in the process. The company’s subsidiaries include Jurong Barrels & Drums Industries Pte. Limited, JBDI Investments Limited, and JBD Systems Pte. Limited.

The enterprise’s products include reconditioned and new open top and bung type steel drums, HDPE/plastic drums, carboys, and intermediate bulk containers (IBCs) with different capacities. Its clients span a range of industries, including the solvent, chemical, petroleum, and edible oil products industries. It also offers ancillary services to its customers, including disposal and col-lection/delivery services, wastewater treatment services, and reconditioning services for used containers.

The firm, which has decades of experience in the industry and has established a strong reputation for quality and reliability, remains committed to generating additional value for its shareholders.

JBDI Holdings (JBDI), closed Tuesday's trading session at $1.1, off by 3.5088%, on 133,961 volume. The average volume for the last 3 months is 10,491,448 and the stock's 52-week low/high is $0.4908/$39.41.

Beeline Holdings (BLNE)

We reported earlier on Beeline Holdings (BLNE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Beeline Holdings (NASDAQ: BLNE) announced the appointment of Frank Knuettel II to its board of directors, effective immediately. Knuettel brings over 20 years of executive leadership experience across early-stage public companies in technology and life sciences, and currently serves as CEO of Channel Therapeutics Corporation. Known for his capital markets expertise and M&A success, including leading Unrivaled Brands from $10 million to $100 million in revenue, Knuettel has raised more than $400 million throughout his career and held key roles at IP Commerce and MJardin Group. His appointment supports Beeline’s growth strategy in the investment lending market.

To view the full press release, visit https://ibn.fm/f5r9h

About Beeline Financial Holdings, Inc.

Beeline Financial Holdings, Inc. is a trailblazing mortgage fintech transforming the way people access property financing. Through its fully digital, AI-powered platform, Beeline delivers a faster, smarter path to home loans—whether for primary residences or investment properties. Headquartered in Providence, Rhode Island, Beeline is reshaping mortgage origination with speed, simplicity, and transparency at its core. The company is a wholly owned subsidiary of Beeline Holdings and also operates Beeline Labs, its innovation arm focused on next-generation lending solutions.

For more information, visit the company’s website at: https://makeabeeline.com/

Beeline Holdings (BLNE), closed Tuesday's trading session at $1.25, up 3.3058%, on 1,305,439 volume. The average volume for the last 3 months is 175,562 and the stock's 52-week low/high is $0.89/$29.8.

Siyata Mobile Inc. (SYTA)

QualityStocks, SeriousTraders, SmallCapRelations, NetworkNewsWire, InvestorBrandNetwork, Stocks to Buy Now, MissionIR, Tip.us, StocksToBuyNow, TechMediaWire, SmallCapSociety, Fierce Analyst, StockWireNews, Small Cap Firm, 360 Wall Street, Broad Street, MarketClub Analysis, Premium Stock Alerts, The Stock Dork, Emerging Markets, StockStreetWire, Kiplinger Today, The Online Investor, Jeff Bishop, MarketBeat, rogueinvesting, Premium Stock Picks, RedChip, TipRanks, Damn Good Penny Picks, Penny Picks, BeatPennyStocks, 247 Market News and Small Caps reported earlier on Siyata Mobile Inc. (SYTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

  • Siyata Mobile is gaining traction across North America with its purpose-built push-to-talk (PTT) devices and Uniden(R)-branded cellular signal boosters.
  • Its SD7 handset offers a rugged, LTE-based replacement for traditional two-way radios in public safety and industrial sectors.
  • Signal boosters enhance connectivity in vehicles, buildings, and remote zones, supporting mission-critical communications.
  • Distribution wins with major U.S. carriers and public sector agencies highlight growing demand and deployment momentum.
  • The company’s carrier-integrated model aligns with rising needs for scalable, reliable communication infrastructure.

Siyata Mobile Inc. (NASDAQ: SYTA) is a technology company providing advanced communication solutions for frontline workers, emergency responders, and mobile workforces. Its core offerings include the SD7 push-to-talk handset and Uniden(R)-branded signal boosters, both designed to improve operational connectivity where traditional networks fall short. These products are FCC- and IC-certified and distributed through Tier-1 carriers, integrators, and government purchasing channels.

The company’s integrated model supports wide-scale deployments across North America, offering a cost-effective alternative to legacy land mobile radios. Siyata is actively expanding in sectors such as logistics, education, and public safety, where communication uptime is essential.

Operations

Siyata’s SD7 device delivers instant, secure LTE-based PTT communication, eliminating the range and cost limitations of legacy systems. Its signal boosters improve cellular performance in vehicles and structures, ensuring coverage in areas with weak reception. Together, these products support customers requiring rugged, dependable connectivity solutions.

Recent deployments include school systems, logistics providers, and local governments. Siyata’s direct alignment with carrier platforms enables broad scalability and integrated provisioning for enterprise and public clients.

Market Opportunity

The global PTT market is projected to grow from $29.9 billion in 2023 to $47.7 billion by 2030, driven by demand for broadband-based communication tools. At the same time, the signal booster market is expected to reach $3.6 billion by 2030. Siyata’s SD7 and Uniden(R) product lines directly address both trends, serving customers who need affordable, reliable mobile communication.

Backed by major carriers and government frameworks, Siyata is positioned to capitalize on these growing sectors with carrier-certified solutions built for scale.

Leadership Team

Marc Seelenfreund, CEO and Founder, brings over 20 years of telecom leadership and spearheads Siyata’s growth strategy.

Peter Goldstein, Chairman, is a capital markets expert with decades of public company experience.

Gerald Commissiong, Independent Director, contributes cross-sector business and governance expertise.

Daniel Kim, CFO, oversees finance and compliance, with a background in SEC reporting and telecom operations.

For more information, visit the company’s website at https://ir.siyata.net.

Siyata Mobile Inc. (SYTA), closed Tuesday's trading session at $8.19, up 101.2285%, on 128,667,790 volume. The average volume for the last 3 months is 322,930 and the stock's 52-week low/high is $0.93/$885.582.

Marathon Digital Holdings Inc. (MARA)

MarketClub Analysis, Schaeffer's, QualityStocks, InvestorPlace, INO Market Report, CryptoCurrencyWire, BillionDollarClub, StockMarketWatch, MarketBeat, StockEarnings, CurrencyNewsWire, StocksEarning, Early Bird, Premium Stock Alerts, TradersPro, Zacks, Investors Underground, FreeRealTime, Lebed.biz, The Online Investor, BUYINS.NET, InvestorsUnderground, Trades Of The Day, 360 Wall Street, TraderPower, Daily Trade Alert, The Street, Marketbeat.com, DailyMarketAlerts, PoliticsAndMyPortfolio, Wall Street Mover, TopPennyStockMovers, The Wealth Report, AllPennyStocks, Wealth Insider Alert, Eagle Financial Publications, MarketClub Options, FeedBlitz, Investment House, StreetAuthority Daily, Kiplinger Today, Top Pros' Top Picks, ProsperityPub, Barchart, RedChip, Wealth Daily, Rick Saddler, TradingPub, Trading Pub, Stock Analyzer, DividendStocks, StreetInsider, Stock Beast, StockReport, Earnings360, Earnings361, StockOodles, Lance Ippolito, Promotion Stock Secrets, Inside Trading, Investment News Daily, Jeff Bishop, Street Insider and DreamTeamNetwork reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The French government is stepping up efforts to protect the cryptocurrency sector by introducing enhanced security measures for industry professionals and their families. Authorities are now offering crypto entrepreneurs priority access to emergency police services, in-home visits by law enforcement, and customized security briefings.

France’s Interior Minister Bruno Retailleau noted that the goal is to both deter attackers and offer real protection to those operating in the digital finance space. Law enforcement personnel are also set to undergo specialized training focused on anti-money laundering within the crypto context. A longer-term initiative to elevate security practices across the sector is also under development.

The move is part of a broader strategy to counteract an increasing number of criminal incidents involving kidnappings and extortion attempts against crypto leaders and their loved ones. Retailleau stressed that the government is not taking these threats lightly.

In parallel, the Association for the Development of Digital Assets plans to educate its members on practical steps they can take to stay safe.

Recent criminal cases have underscored the urgency. Criminal gangs have tried to kidnap family members of crypto executives. In one high-profile case, masked men attempted to abduct the daughter and grandson of a Paymium executive in broad daylight. The attempt failed thanks to the executive’s quick intervention.

In other cases, victims were not so lucky—two men kidnapped earlier this year each lost a finger before being rescued.

The country’s organized crime units are currently handling the investigations, and multiple suspects have been taken into custody. Authorities suspect that these cases are linked and part of a larger pattern.

The pseudonymity of blockchain makes it difficult to trace illicit transactions, making crypto appealing to criminals. Digital assets are also easy to move, hold value well, and can be transferred instantly, making them attractive targets.

Some industry leaders argue that stricter regulations, like those requiring identity checks for crypto transfers, might ironically make things worse. They believe more anonymity could increase safety by making it harder for criminals to identify and target individuals.

Others have responded by taking private precautions. Some executives are hiring security personnel, avoiding public transportation, and staying under the radar. Alexandre Aimonino, co-founder of a crypto compliance startup, admitted he has adjusted his daily routine to avoid becoming a target.

While cryptocurrencies remain a small fraction of the global financial system, their rapid value growth has made crypto entrepreneurs high-profile targets. Still, experts caution that not everyone in the industry is wealthy, and while vigilance is necessary, widespread panic isn’t.

The developments in France are likely to be followed closely by crypto industry players like Marathon Digital Holdings Inc. (NASDAQ: MARA) in other parts of the world since what is happening there could be a harbinger of what could happen in those other markets.

Marathon Digital Holdings Inc. (MARA), closed Tuesday's trading session at $16.19, off by 0.7965686%, on 34,242,557 volume. The average volume for the last 3 months is 1,179,957 and the stock's 52-week low/high is $9.81/$30.28.

B. Riley Financial Inc. (RILY)

Schaeffer's, InvestorPlace, BillionDollarClub, InsiderTrades, The Online Investor, The Wealth Report, QualityStocks, MarketBeat, Daily Trade Alert, StreetInsider, Marketbeat.com, MarketClub Analysis, Wealth Insider Alert, TraderPower, 360 Wall Street, DividendStocks, StockMarketWatch, StreetAuthority Daily, Investors Underground, The Street, Top Pros' Top Picks, BUYINS.NET, Trades Of The Day and Premium Stock Alerts reported earlier on B. Riley Financial Inc. (RILY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Standard Chartered, also known as Stanchart, is making big moves in the world of investment banking. The bank has set up a new team in the United States to focus on private equity firms, hedge funds, and other big financial investors. This is part of its plan to grow its investment banking business and earn more from financial clients.

The new team will be based in New York, but it will also have offices in London and Dubai. At the start, the team will have around 25 bankers. Some of them will be hired from outside the company. Stanchart says it will name a global head for this team soon. Until then, Molly Duffy, one of the bank’s senior leaders, will take charge.

So why is Stanchart doing this? Right now, financial clients like banks, insurance companies, and investment firms already bring in more than half of the bank’s income from investment banking. These clients usually provide higher profits, so Stanchart wants to build stronger relationships with them and win more of their business.

This move shows how serious the bank is about growing its global presence, especially in the U.S. It also comes at a time when other banks are going in the opposite direction. For example, HSBC has recently pulled back from some of its U.S. and European investment banking activities to focus more on Asia.

Stanchart’s strategy is different. Instead of cutting back, it is expanding and trying to build better connections with American financial firms. This new team is also part of a bigger plan the bank started last year, which includes setting up groups to handle large international deals.

Sunil Kaushal, who helps lead the bank’s corporate and investment banking section, says Stanchart is putting more effort into serving private equity clients. At the same time, the bank is also targeting other financial institutions like asset managers and insurance firms.

This announcement was made during a special presentation to investors, where the bank explained its plans and strategy in more detail. It’s clear that Stanchart wants to stay competitive and grow its profits by focusing on clients that bring in strong returns.

In short, Stanchart is not backing down. It is stepping up and going after bigger deals in the U.S., with a special team ready to build strong financial partnerships around the world. Investment banking firms like B. Riley Financial Inc. (NASDAQ: RILY) will not be overly concerned by Stanchart’s foray since the investment banking market is a large one and there is a place for everyone who can offer their services.

B. Riley Financial Inc. (RILY), closed Tuesday's trading session at $3.27, up 1.5528%, on 368,326 volume. The average volume for the last 3 months is 309,999 and the stock's 52-week low/high is $2.67/$33.

The QualityStocks Company Corner

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central nervous system disorders.

The company's lead candidate, NRX-100 (preservative free IV ketamine), NDA in process with the FDA, has been granted Fast Track designation by the FDA for acute suicidal depression, and a patent for this novel formulation has been filed with the U.S. Patent and Trademark Office.

NRX-101 (oral D-cycloserine/lurasidone) , has received FDA Breakthrough Therapy designation, expediting its development.

HOPE Therapeutics, NRx's interventional psychiatry subsidiary, is targeting $100M in forward looking revenue by year-end 2025, through development of a national clinic network treating suicidal depression, treatment-resistant depression, PTSD and related central nervous system ("CNS") disorders.

The company's experienced leadership team has a proven track record in pharmaceutical development and commercialization.

NRx is positioned to address large and growing markets with its novel depression treatments, non-opioid therapeutic solutions and directly helping patients in HOPE clinics nationwide.

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, particularly suicidal depression and PTSD. The company is leveraging its patented NMDA receptor modulation platform with two drugs, NRX-100 (preservative-free ketamine) and NRX-101 (D-cycloserine/lurasidone), that have received FDA Fast Track and Breakthrough Therapy designations, respectively. Both address acute unmet medical needs, in that there is no FDA-approved medication for suicidal depression and PTSD. The only approved treatment today is electroshock therapy.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

  • NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
  • NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
  • Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

Investment Considerations
  • NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting significant unmet needs in central nervous system disorders.
  • The company’s lead candidate, NRX-101, has received FDA Breakthrough Therapy designation, expediting its development.
  • NRX-100 (preservative free IV ketamine) has been granted Fast Track designation by the FDA for acute suicidal depression a patent for this novel formulation has been filed with the US Patent and Trademark Office.
  • HOPE Therapeutics, NRx’s interventional psychiatry subsidiary, is targeting $100M in revenue by year-end 2025 through a national clinic network treating suicidal depression and PTSD.
  • The company’s experienced leadership team has a proven track record in pharmaceutical development and commercialization.
  • NRx is positioned to address large and growing markets with its novel depression treatments, non-opioid therapeutic solutions and directly help patients in HOPE clinics.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Tuesday's trading session at $2.78, up 13.9344%, on 62,455 volume. The average volume for the last 3 months is 237,261 and the stock's 52-week low/high is $1.1/$6.01.

Recent News

SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

CEO Dr. Richard Lu discussed SolarBank's vertically integrated business model on a recent GotStocks podcast.

SolarBank is an expanding developer, builder, operator, and owner of clean energy projects across North America, maintaining a $184 million portfolio of assets generating recurring revenue.

The company's flexible supply chain strategy helps mitigate any tariff risks while reducing costs.

Going forward, a recently announced up to $100 million transaction with CIM Group is set to fund up to 97 MW of U.S. community solar projects.

Disseminated on behalf of SolarBank Corporation

Dr. Richard Lu, CEO of SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) , a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., offered insights into the company's operations, strategy, and unique competitive position during a recent interview on IBN's GotStocks podcast ( https://ibn.fm/UCIdQ ). The conversation centered on SolarBank's dual role as both a developer and long-term owner of solar energy assets, an approach that differentiates the firm in a competitive market.

The global adoption of battery electric vehicles (BEVs) is having a notable effect on oil demand across several key markets. Oil has been the primary source of energy for the transport industry for over a century, and a large portion of the world's infrastructure grew around the extraction, refining, and distribution of oil and petroleum products. Although this reliance on oil has significantly contributed to premature atmospheric heating and accelerated climate change, fossil fuels were integral to the transport sector and several other energy-intensive industries. As automobiles became common and urban centers across the globe increasingly centered their infrastructure around vehicles, the demand for fossil fuels continued to skyrocket. However, concerns regarding the role of fossil fuels like oil, natural gas, and coal in climate change have caused dozens of countries worldwide to begin transitioning to cleaner and more sustainable alternatives. Green infrastructure like EVs, solar panels, and wind turbines has gained major traction amidst the transition to renewable energy. The global adoption of EVs is steadily reducing the world's dependence on oil by cutting demand in the transportation sector, one of the largest consumers of petroleum. Over time, widespread EV adoption could significantly curb global oil consumption, reducing emissions and fostering a more sustainable energy future. As more companies like SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) continue to make inroads into the energy storage and EV battery market segments, we are likely to see further reductions in the amount of oil used around the world as more people charge their EVs using renewable energy.

SolarBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. SolarBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, SolarBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, SolarBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

SolarBank has offices in Toronto, Ontario and New York.

Projects

SolarBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, SolarBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of SolarBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, SolarBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

SolarBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

SolarBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance SolarBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, SolarBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of SolarBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of SolarBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive SolarBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by SolarBank, enhancing its asset portfolio and growth prospects.


Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

SolarBank Corp. (NASDAQ: SUUN), closed Tuesday's trading session at $1.87, up 2.7473%, on 156 volume. The average volume for the last 3 months is 141,621 and the stock's 52-week low/high is $1.7901/$6.7.

Recent News

Intelligent Bio Solutions Inc. (NASDAQ: INBS)

The QualityStocks Daily Newsletter would like to spotlight Intelligent Bio Solutions Inc. (NASDAQ: INBS).

Medical technology company Intelligent Bio Solutions has launched Arabic, Italian, and Spanish websites to support expansion into key international markets.

The move opens digital access to over 1.4 billion people across Latin America, the Middle East, and Southern Europe.

The rollout aligns with increased demand for non-invasive workplace drug testing and compliance tools.

INBS's flagship fingerprint sweat-based drug screening system is currently used by over 450 clients in 24 countries.

The company plans a U.S. market launch in 2025 as it continues to develop additional biosensor applications.

Intelligent Bio Solutions (NASDAQ: INBS) , a medical technology company specializing in rapid, non-invasive testing solutions, is expanding its international footprint by launching localized websites in Arabic, Italian, and Spanish. The initiative is part of the firm's strategy to boost commercial activity across high-potential regions with growing demand for workplace safety and compliance solutions ( https://ibn.fm/odRAg ).

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings such as opiates, cocaine, methamphetamine, and cannabis. This innovative approach positions INBS to transform drug testing protocols, particularly in industries where safety and speed are mission critical.

The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system empowers companies and organizations to screen more efficiently. INBS continues to drive adoption in international markets, with customers spanning construction, logistics, healthcare, government, and drug treatment sectors.

INBS’s mission is centered on delivering accessible, transformative solutions that improve lives and operational safety. As the company expands toward a planned U.S. market launch in 2025, it is also strengthening its intellectual property portfolio and localizing solutions for Spanish-speaking regions.

The company is headquartered in New York, New York.

Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions’ flagship offering is the Intelligent Fingerprinting Drug Screening System, a portable, three-part solution that includes a fingerprint collection cartridge, a lateral flow-based DSR-Plus reader, and software for rapid drug screening. Designed to be used on-site, this system eliminates the complexities and hazards of urine and saliva tests, offering a clean, fast, and non-invasive alternative.

The system screens for a broad range of substances including opiates, methamphetamine, cocaine, cannabis, benzodiazepines, and more. Its cost advantage is significant — point-of-care fingerprint tests cost approximately $20, compared to $300 for typical urine or saliva testing. The platform includes over 1,000 DSR-Plus Readers installed across customer sites, supporting a base of more than 450 active customer accounts globally. In clinical studies, the system demonstrated 94.1% accuracy and 100% specificity, providing a credible foundation for future FDA approvals and market expansion.

In addition to drug screening, INBS is developing a proprietary biosensor platform designed to detect specific biomarkers from non-invasive samples such as sweat, saliva, and interstitial fluid. These additional applications remain under development.

Market Opportunity

Intelligent Bio Solutions operates at the intersection of workplace safety, public health, and diagnostic innovation. The company is targeting the drug screening products market, which is projected to reach $14.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.1%, according to Research and Markets.

In the U.S., substance abuse is a $400 billion issue, with more than 70% of individuals using illicit drugs or alcohol currently employed. This presents an urgent need for scalable, workplace-compatible screening technologies. Industries such as transportation, construction, mining, and healthcare are among the highest adopters of employee drug testing protocols, driven by regulatory requirements and safety imperatives.

INBS’s non-invasive solution is well-positioned to capitalize on trends toward less invasive, faster, and more convenient testing methods — potentially displacing legacy systems reliant on urine or saliva testing, which have longer turnaround times and greater administrative burdens.

Leadership Team

Harry Simeonidis, Chief Executive Officer, has over 25 years of experience across the healthcare, pharmaceutical, and life sciences industries. He previously served as General Manager for Surgery, Asia Pacific at GE Healthcare. Prior to that, he was President and CEO of GE Healthcare ANZ, where he led significant market share growth.

Spiro Sakiris, Chief Financial Officer, brings 34 years of expertise in accounting, taxation, IPO preparation, and capital raising. He is highly experienced with IFRS and U.S. GAAP applications in the life sciences sector and is a member of the Institute of Chartered Accountants of Australia & New Zealand.

Investment Considerations
  • INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030.
  • The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts.
  • Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods.
  • The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway.
  • INBS is led by a seasoned executive team with global healthcare and commercialization experience.

Intelligent Bio Solutions Inc. (NASDAQ: INBS), closed Tuesday's trading session at $1.28, up 3.6437%, on 1,120 volume. The average volume for the last 3 months is 103,276 and the stock's 52-week low/high is $1/$3.

Recent News

FAVO Capital Inc. (OTC: FAVO)

The QualityStocks Daily Newsletter would like to spotlight FAVO Capital Inc. (NASDAQ: FAVO).

Momentum suggests a positive trajectory in the private credit market in the coming year.

FAVO Capital offers flexible capital solutions tailored to SMBs' unique needs.

The company's approach exemplifies how private credit firms are leveraging technology to enhance their offerings.

The private credit market is on the cusp of substantial expansion in 2025, driven by a resurgence in global mergers and acquisitions ("M&A"), the digitization of lending processes and the emergence of innovative financing solutions tailored for small and medium-sized businesses ("SMBs") ( https://ibn.fm/pDNA4 ). This confluence of factors is reshaping the financial landscape, as companies such as FAVO Capital (OTC: FAVO) are strengthening their foothold in the growing space.

FAVO Capital Inc. (OTC: FAVO) is redefining the private credit and alternative lending industry through a strategic redevelopment of its operations and offerings. With a focus on leveraging financial technology and a client-centric approach, FAVO Capital empowers small to medium-sized businesses with fast, flexible, and reliable access to capital, bridging the gap left by traditional financial institutions.

Empowering Businesses, Redefining Private Credit

As part of its strategy to uplist to Nasdaq, FAVO Capital is enhancing its technology platform, operational scalability, and market positioning to meet higher regulatory standards and attract institutional investors. Headquartered in Fort Lauderdale, Florida, FAVO employs over 120 professionals across five global offices, delivering sustainable growth and value for clients and shareholders alike.

Products and Services

  • Proprietary Lending Platform and Mobile App (In Development): FAVO Capital is in the early stages of developing an advanced digital platform designed to enhance client engagement and streamline funding processes. This platform will eventually allow businesses to apply for funding products, track progress, and manage repayment efficiencies. A complementary mobile app is also being planned to provide real-time insights and tailored recommendations, laying the groundwork for an improved borrower experience.
  • Fintech-Driven Lending Solutions: FAVO Capital is exploring proprietary and third-party technology tools, including advanced analytics and algorithms, to enhance decision-making speed and reliability in the lending process.
  • Flexible Financing Options: FAVO specializes in structuring customized capital solutions tailored to the diverse needs of small business owners, offering scalable and adaptable products that evolve with changing market conditions.

Market Opportunity

The private credit market is experiencing exponential growth as traditional banks reduce their focus on small business lending. According to industry reports, the global private credit market is projected to surpass $1.5 trillion by 2025, driven by increasing demand for alternative financing options.

FAVO Capital is uniquely positioned to capture market share within this booming sector by leveraging fintech innovation to meet the needs of underserved small businesses. With a focus on efficiency, speed, and client satisfaction, FAVO addresses critical gaps in the financial ecosystem while building a platform for long-term growth.

Recent Highlights

  • Fintech Innovation: Initial investments in app development and analytics lay the groundwork for future operational efficiency and improved borrower experience.
  • Operational Scale: A global footprint with over 120 employees combines the agility of a local lender with the reach of an international financial institution.
  • Proven Growth: FAVO’s technology-driven approach has enabled consistent expansion, solidifying its reputation as a trusted partner for small businesses.

Leadership Team

Vincent Napolitano is a Founder and CEO of FAVO Capital Inc. With over two decades of experience in finance and business development, Vincent has been instrumental in building FAVO Capital into a trusted partner for businesses seeking innovative financial strategies. Prior to founding FAVO Capital, Vincent spent 25 years on Wall Street, holding key positions at prominent firms and developing expertise in structuring complex financial deals. He also served as Chief Investment Officer for multiple special purpose vehicles (SPVs), acquiring private stock in pre-IPO unicorn companies such as Facebook and Twitter.

Shaun Quin is a Founding Member and President of FAVO Capital Inc., overseeing the company’s mission to deliver innovative and efficient private credit solutions to small and medium-sized businesses. With over 20 years of global experience as a partner, investor, and director, Shaun brings a strategic and customer-focused approach to his leadership. His expertise in fostering collaboration, building high-performance cultures, and empowering businesses has positioned FAVO Capital as a trusted leader in private lending.

Vaughan Korte, CFO, brings over 15 years of global financial expertise to his role with FAVO Capital Inc. His track record includes managing financial operations for Adidas across 60 countries with budgets exceeding $500 million. Vaughan’s leadership ensures FAVO Capital remains financially resilient, aligning financial strategy with organizational goals and fostering shareholder value.

Glen Steward, Chief Strategy Officer, is a seasoned entrepreneur with over 28 years of experience in the investment and trading industries. He drives FAVO Capital’s strategic initiatives, ensuring the company remains competitive and agile in a rapidly evolving market. Glen has held directorships and board memberships across Mauritius, South Africa, and the United States. His strategic acumen has been pivotal in integrating the FAVO Group of Companies into FAVO Capital Inc., fueling growth and market leadership.

Advisory Board

Bilal Adam, Accounting & Financial Counsel, is a financial expert with over 20 years of experience, including roles as CEO of Stewards Investment Capital. His insights into bespoke investment solutions, including fixed income, equity, and digital assets, support FAVO Capital’s innovative approach to private credit.

Honorable Earnest Hart, Corporate Governance Counsel, brings decades of legal and governance experience, having served as a New York Supreme Court Judge and COO at Columbia University Medical Center. His guidance ensures FAVO Capital maintains robust corporate governance standards.

Rocco Trotta, Business Leadership and Scalability Counsel, is the co-founder of LiRo-Hill and has decades of experience scaling businesses. His expertise in organizational efficiency and talent development strengthens FAVO Capital’s ability to attract excellence across all aspects of the business.

As FAVO Capital redevelops its operations and prepares for an uplisting to Nasdaq, the company is laying the foundation to redefine private credit with emerging fintech solutions and exceptional leadership. Learn more by visiting investors.favocap.com.

Investment Considerations
  • Early-Stage Technology Development: Laying the groundwork for proprietary platforms and scalable digital tools.
  • Significant Market Opportunity: The private credit market is projected to exceed $1.5 trillion by 2025, providing exponential growth potential.
  • Scalable Business Model: Automated processes and data-driven decision-making enable rapid scaling with minimal overhead.
  • Customer-Centric Approach: FAVO’s focus on small businesses and flexible financing solutions addresses critical gaps in the financial ecosystem.
  • Experienced Leadership: A forward-thinking executive team ensures strategic growth and innovation.

FAVO Capital Inc. (OTC: FAVO), closed Tuesday's trading session at $1.05, even for the day, on 200 volume. The average volume for the last 3 months is 140 and the stock's 52-week low/high is $0.162/$1.45.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN) reported $5 million in revenue for the quarter ended March 31, 2025, a significant increase from $33,000 in the prior-year period, driven by deliveries of Class 1 and Class 3 electric vehicles to customers including logistics firms, local governments and universities. The company also highlighted new agreements, such as a supply deal with Enpower Greentech for advanced solid-state batteries and expanded public sector eligibility via Sourcewell contracts. Bollinger Motors, a majority-owned subsidiary, delivered Class 4 trucks but was placed into court-appointed receivership in May, a move Mullen says will not materially impact its liquidity. For the six-month period, Mullen recorded $7.9 million in revenue and a net loss of $162 million, with $118 million tied to non-cash expenses. Cash on hand declined to $2.3 million, and the company is continuing cost-reduction efforts and financing through convertible securities.

To view the full press release, visit https://ibn.fm/kS3g8

Tesla's brand image has taken a significant hit in recent months. For at least a decade, Tesla was the darling of the burgeoning global electric vehicle segment. After launching the Tesla Roadster in 2008 and demonstrating the viability of mass market battery electric vehicles (BEVs), Tesla remained the most dominant player in the EV sector for most of its existence. Until very recently, Teslas were among the most popular electric cars on the global market, and the Tesla Model Y was the bestselling EV worldwide in 2024. However, 2025 has proven to be a disastrous year for the Texas-based electric vehicle firm. Consumers in several key markets are turning away from the once-beloved automaker. With a battered brand imagedeclining demand, rising competition, and growing regulatory pressure, Tesla is facing challenges that threaten its dominance in the EV sector, and perhaps even its long-term survival. How the company navigates this turbulent period will determine whether it remains a market leader or fades into the background of a rapidly evolving industry. As Tesla's grip on the EV market loosens, all eyes will be on emerging players like Mullen Automotive Inc. (NASDAQ: MULN) that are focused on making their mark on this rapidly-evolving industry.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $0.1995, off by 41.3235%, on 2,530,829 volume. The average volume for the last 3 months is 36,920,839 and the stock's 52-week low/high is $0.1458/$2868000.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $16.56, up 25.9316%, on 23,109,675 volume. The average volume for the last 3 months is 66,274,222 and the stock's 52-week low/high is $0.7505/$17.59.

Recent News

Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG)

The QualityStocks Daily Newsletter would like to spotlight Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG).

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) is the operator of the Waterberg Project, a bulk underground platinum group metals (PGM) deposit discovered by Platinum Group in 2011 and located on the Northern Limb of the Bushveld Complex in South Africa. The Waterberg Project is planned as a fully mechanised platinum, palladium, rhodium and gold mine, including by-product copper and nickel production, and is projected to be one of the largest and lowest cost PGM mines globally.

The project is a joint venture between Platinum Group; integrated PGM producer Impala Platinum Holdings Ltd. (OTCQX: IMPUY); Japanese consortium HJ Platinum, which includes trading house Hanwa Co. and the government-backed Japan Organization for Metals and Energy Security (JOGMEC); and local empowerment partner Mnombo Wethu Consultants (Pty) Ltd. Platinum Group has an effective 50.22% interest in the Waterberg Project.

The company’s primary business objective is to advance the Waterberg Project to a development and construction decision. An update to the 2019 Definite Feasibility Study is expected in 2024.

PGMs are essential and precious metals that include platinum, palladium, rhodium, iridium, osmium and ruthenium. These metals are known for their purity, high melting points and unique catalytic properties. They are utilized in a number of industrial processes, technologies and commercial applications and play a critical role in autocatalysis and pollution control in the automotive sector. The bulk of global PGMs are mined in Southern Africa and Russia.

The unique properties of PGMs are being applied to various technologies as possible solutions for more efficient energy generation and storage, which may create new demand for PGMs. The company’s battery technology initiative through Lion Battery Technologies Inc., using platinum and palladium in lithium battery technologies, represents one such new opportunity in the high-profile lithium battery research and innovation field.

Platinum Group Metals Ltd. founded Lion Battery Technologies Inc. in partnership with Anglo American Platinum Ltd. (AMS: JNB) to support the use of palladium and platinum in lithium battery applications. Lion Battery has entered into an agreement with Florida International University to further advance a research program that uses platinum and palladium to unlock the potential of Lithium Sulfur (Li-S) battery chemistries.

Platinum Group is headquartered in Vancouver, B.C., and Johannesburg, South Africa.

Waterberg Project

Platinum Group’s sole material mineral property, the Waterberg Project, is presently in process with pre-construction permitting; engineering work, including road upgrade and traffic studies; finalization of power and water infrastructure design; and construction camp design.

The company’s principal product from the Waterberg Project is planned to be a PGM-bearing concentrate. The concentrate will contain economic amounts of six elements comprising platinum, palladium, rhodium, gold, copper and nickel. The company’s partner in the Waterberg Project, Impala Platinum Holdings, has acquired a right of first refusal to enter into an offtake agreement, on commercial arm’s-length terms, for the smelting and refining of mineral products from the Waterberg Project.

The Waterberg project has proven and estimated reserves of 19.5 million ounces of PGMs and gold. When fully operational, the mine is projected to produce more than 400,000 ounces of PGMs annually during the peak period of steady state production. The life of the mine is projected at 45 years.

South Africa’s PGM mining sector remains closely tied to economic developments in the global automotive industry, which in 2022 accounted for approximately 43% of the total global demand for platinum and 82% of the total global demand for palladium.

Market Opportunity

According to a report from Straits Research, a global market and business research firm, the worldwide platinum market had an estimated value of $7.72 billion in 2022 and is projected to reach $11.95 billion by 2031. That represents a CAGR of 5.13% over the forecast period.

Platinum, one of the rarest of precious metals, is about 30 times scarcer than gold. It is crucial to the automotive and electronics industries and is also used to make jewelry. Stricter emissions regulations around the world have led to an increased demand for platinum to be used in catalytic converters to reduce automotive emission, the report states.

A report from Allied Market Research estimated the global palladium market at $16.3 billion in 2021 and projects the market will reach $28.6 billion by 2031, growing at a CAGR of 5.8% over the period.

Palladium is also used in automotive catalytic converters for reducing emissions and in jewelry, dentistry, watchmaking, blood sugar test strips, aircraft spark plugs, surgical instruments, electrical contacts and musical instruments.

An increase in demand for consumer electronics has driven demand for palladium-based multilayer ceramic capacitors (MLCC) used to store energy in electronic devices such as broadcasting equipment, mobile telephones, computers, electronic lighting and high voltage circuits, according to the report.

Management Team

Frank R. Hallam is Co-Founder, Director, President and CEO of Platinum Group. He has over 30 years of experience in the mining, minerals and petroleum industry as an operator, principal and founder. He was a co-founder and former CFO of MAG Silver Corp. He was also co-founder and director of West Timmins Mining Inc. and a director of Lake Shore Gold Corp. In addition, he was CFO and director with gold exploration company Tan Range Exploration Corp. He is a Chartered Professional Accountant and was formerly an auditor in the public mining practice of PwC. He holds a Bachelor of Business Administration from Simon Fraser University.

Greg Blair is CFO of Platinum Group. He has been with Platinum Group since 2010 in various roles, most recently as Interim CFO. Prior to joining Platinum Group, he was at a public accounting firm working on public company (mainly mining) audits. He is a Chartered Professional Accountant and holds a degree in Economics from Simon Fraser University and has completed the Canadian Securities Course.

Kris Begic is VP Corporate Development of Platinum Group. He has over 25 years of experience in the mining industry and capital markets and has been involved with the raising of over $500 million for various exploration and development projects globally. His efforts are focused on project generation, mergers and acquisitions, capital markets, investor relations and marketing.

Platinum Group Metals Ltd. (NYSE American: PLG), closed Tuesday's trading session at $1.32, up 14.7826%, on 24,856 volume. The average volume for the last 3 months is 696,970 and the stock's 52-week low/high is $0.99/$2.27.

Recent News

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

  • NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
  • SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
  • RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Tuesday's trading session at $0.446, up 6.6986%, on 6,124 volume. The average volume for the last 3 months is 212,622 and the stock's 52-week low/high is $0.35/$4.9.

Recent News

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Investment Considerations
  • Soligenix has multiple late-stage assets with orphan and fast-track designations, providing a clear regulatory pathway toward potential approvals.
  • The company’s pipeline has a total addressable market exceeding $2 billion, spanning rare diseases, inflammation, and biothreat applications.
  • Soligenix has benefited from significant non-dilutive government funding, which reduces operational expenses and financial risk while supporting its public health initiatives.
  • The company is well-positioned for multiple development and regulatory catalysts, and commercial milestones, with lead candidates in cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease.
  • Soligenix is led by an experienced management team with a strong track record of success.

Soligenix Inc. (NASDAQ: SNGX), closed Tuesday's trading session at $1.97, up 4.7872%, on 1,229 volume. The average volume for the last 3 months is 32,824 and the stock's 52-week low/high is $1.68/$14.8299.

Recent News

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Additional Resources

Brera Holdings PLC (NASDAQ: BREA), closed Tuesday's trading session at $0.708, up 4.4248%, on 342 volume. The average volume for the last 3 months is 70,689 and the stock's 52-week low/high is $0.4999/$1.95.

Recent News

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

Investment Considerations
  • Fully Permitted & Funded for Near-Term Production: Construction underway soon at Montauban with gold-silver production expected in Q3 2025.
  • Tailings-to-Cashflow Strategy: Near-term cash flow from processing historic tailings will fund exploration across the district-scale land package.
  • Replicable Clean Mining Model: Scalable approach to legacy mine redevelopment in Canada and globally.
  • Broken Hill Analogue: Geological and structural parallels suggest Montauban may host a larger, mineralized system at depth.
  • Modern 3D Imaging Tech: Cutting-edge ANT survey is producing subsurface imaging beyond 800m, uncovering the potential size of the deposit.

ESGold Corp. (OTCQB: ESAUF), closed Tuesday's trading session at $0.34, up 3.3435%, on 103,499 volume. The average volume for the last 3 months is 111,920 and the stock's 52-week low/high is $0.0221/$0.5.

Recent News

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF)

The QualityStocks Daily Newsletter would like to spotlight Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF).

Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade mineral assets in British Columbia. With a unique dual-pronged model, the company combines solid operational revenues from its wholly-owned, state-of-the-art gold and silver mill with the long-term upside of 100%-owned copper, silver, and gold exploration projects. This approach allows Nicola to fund ongoing development while minimizing equity dilution.

The company’s strategy centers on aligning infrastructure and permitting advantages with mineral-rich geology, positioning it to process its own, as well as third-party high-grade gold and silver mines via partnerships, to advance its own exploration targets. Key agreements with gold producers and concentrating sales contracts provide stable cash flow, making Nicola rare among juniors in its ability to internally support growth. Its solid balance sheet and business acumen have allowed it to take stakes in other near-term gold producers, including a 75% economic stake in Dominion Gold, which commences a bulk sample in 2H 2025.

Nicola is leveraging its platform of permitted infrastructure, strategic project locations, and deep technical expertise to build shareholder value in a low-risk, high-reward framework. The company is headquartered in Vancouver, British Columbia.

Projects

Nicola Mining’s project portfolio includes high-grade copper, silver, and gold assets located in mineral-rich regions of British Columbia. Each project is 100%-owned or majority-controlled, with strong exploration potential and the necessary permits to advance development.

New Craigmont Copper Project

Nicola’s flagship asset, the New Craigmont Project, is a historic producer of over 900 million pounds of copper. Since acquiring 100% ownership in 2015, the company has drilled over 18,000 meters and identified significant skarn-hosted and porphyry-style mineralization. Recent drilling in 2024 confirmed 52.9 meters at 1.03% Cu (Hole NC-24-002), supporting the presence of a large-scale copper system. The project benefits from paved road access, connection to BC Hydro’s grid, and proximity to urban centers.

Treasure Mountain Silver Project

This 100%-owned past-producing mine has a Major Mines permit (M-239) and an NI 43-101 compliant resource estimate. The site includes multiple silver-lead-zinc veins and is permitted to extract up to 60,000 tonnes annually. Nicola is evaluating potential reactivation or joint venture options. Resource estimates include indicated resources of 52,000 tonnes grading 18.1 oz/t Ag, 3.26% Pb, and 3.4% Zn, and inferred resources of 161,000 tonnes grading 22.0 oz/t Ag, 2.48% Pb, and 3.86% Zn.

Dominion Creek Project (Au-Ag)

Nicola holds a 50% land ownership and 75% economic stake in this gold-silver project. Located 43 km from Wells, British Columbia, the site has returned grab samples averaging 61.3 g/t Au and 173.7 g/t Ag. The company has received its final permit and plans to extract a 10,000-tonne bulk sample in 2025, which will be processed at its Merritt Mill facility.

Operations

In addition to its exploration assets, Nicola Mining operates a suite of permitted industrial facilities in British Columbia that generate revenue and support the company’s broader development strategy. These assets form the backbone of Nicola’s self-sustaining business model.

Merritt Mill & Tailings Facility

Nicola owns and operates British Columbia’s only provincially permitted toll mill for gold and silver, a $30 million flotation facility located near Merritt. Gold production began in 2023. The facility is supported by long-term Milling and Profit Share Agreements with companies including Osisko Development Corporation, Blue Lagoon Resources, and Talisker Resources.

Sand & Gravel Pit / Rock Quarry / Ready-Mix Concrete Plant

Nicola also operates a permitted gravel pit (100,000 t/year), rock quarry (1,500 t/day), and is set to launch a ready-mix cement plant in Q2 2025. These operations, run in partnership with local First Nations, generate stable cash flow to support exploration efforts.

Market Opportunity

Nicola Mining is uniquely positioned in southern British Columbia, a jurisdiction recognized for its mining-friendly policies, skilled labor force, and robust infrastructure. The New Craigmont Project is geologically situated within the Guichon Creek Batholith, a region hosting some of Canada’s largest copper mines, including Highland Valley. Exploration data from 2023 and 2024 support the potential presence of both skarn and porphyry systems, increasing the strategic value of Nicola’s holdings.

The company’s other assets, including Treasure Mountain and Dominion Creek, are located in historically productive areas with high-grade mineralization and established access routes. Dominion Creek, in particular, sits atop the Isaac Lake Fault system—identified in British Columbia’s RGS (Regional Geochemical Survey) as a highly anomalous gold-silver corridor. Nicola’s integrated production model enables it to generate revenue while advancing these exploration programs without excessive dilution, providing a distinct advantage in a volatile commodities market.

Leadership Team

Peter Espig, Chief Executive Officer & Director, is a former diamond driller who spearheaded Nicola through a restructuring into its recent growth. He brings over $2 billion in private equity transaction experience, is a pioneer of SPACs, and has held senior positions at Goldman Sachs Japan and Olympus Capital.

Will Whitty, VP of Exploration, brings to the company over 15 years of experience in copper and gold exploration. He previously worked at Freeport-McMoRan and Nevada Gold Mines. He holds a master’s degree from the Mineral Deposit Research Unit (MDRU) at the University of British Columbia.

Bill Cawker, Corporate Development, manages investor relations, communications, and corporate governance. He joined Nicola in 2023 and brings extensive small-cap public markets experience, along with a degree in economics from the University of British Columbia.

Sam Wong, Chief Financial Officer, is a CPA with over 18 years of experience in the mining sector. He previously held executive roles at several publicly listed resource companies. He began his career at Deloitte LLP in Vancouver.

Investment Considerations
  • High-Grade Copper Opportunity: 100% ownership of the New Craigmont Project, one of British Columbia’s most promising high-grade copper exploration targets, strategically located adjacent to Canada’s largest copper mine (Highland Valley Copper).
  • Immediate Revenue Generation: Operates British Columbia’s only permitted mill capable of processing third-party gold and silver ore, with current throughput supporting strong, near-term cash flow.
  • Diverse Revenue Streams: Revenue growth fueled by commercial milling operations, gold concentrate sales, and active aggregate production — providing self-funded exploration and reducing reliance on capital raises.
  • Strategic Location & Infrastructure: Centrally located near major transportation routes and mining services, providing cost advantages and operational efficiencies.
  • Proven Leadership Team: Led by a management group with extensive track records in mining operations, project development, and capital markets, driving disciplined growth and long-term value creation.

Nicola Mining Inc. (OTCQB: HUSIF), closed Tuesday's trading session at $0.267, up 0.0562114%, on 10,762 volume. The average volume for the last 3 months is 59,800 and the stock's 52-week low/high is $0.1498/$0.3024.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.